ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
39.38
0.74%
US Tech 100
20,836.00
1.31%
S&P 500
5,930.85
1.09%
US Dollar vs CAD
1.43625
0.14%
Bitcoin
95,856.94
-1.39%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Humacyte Inc (HUMA)

  7. Humacyte Inc (HUMA) News

Humacyte Inc

Humacyte Inc (HUMA)

NASDAQ
4.64
1.18
(34.10%)
Closed December 22 3:00PM
Delayed by 15 minutes
4.75
0.11
(2.37%)
After Hours: 6:59PM
Delayed by 15 minutes

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

HUMA News

Official News Only

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 03 2024
HUMA (34.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 03 2024
HUMA (34.10%)

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
Edgar (US Regulatory)
September 03 2024
HUMA (34.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
August 29 2024
HUMA (34.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
August 29 2024
HUMA (34.10%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
August 29 2024
HUMA (34.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
August 29 2024
HUMA (34.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
August 28 2024
HUMA (34.10%)

Form 144 - Report of proposed sale of securities
Edgar (US Regulatory)
August 27 2024
HUMA (34.10%)

HUMA Discussion

View Posts
Monksdream Monksdream 22 hours ago
HUMA under $5

[color=red][/color]
👍️0
threebabiesbusy threebabiesbusy 2 days ago
Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
👍️0
threebabiesbusy threebabiesbusy 2 days ago
Let's push through the $4.80 wall!
👍️0
threebabiesbusy threebabiesbusy 2 days ago
awww so you're out. Looks difficult for afternoon move up
👍️0
threebabiesbusy threebabiesbusy 2 days ago
We're trading substantially below days VWAP....
👍️0
threebabiesbusy threebabiesbusy 2 days ago
Lunch time pull back. Do you anticipate afternoon trend back up? Or do we call it one and done!
👍️0
TrendTrade2016 TrendTrade2016 2 days ago
EXITED ON THAT PUSH BOTTOM BOUNCE
👍️0
Tiger Money Tiger Money 2 days ago
Love having you back.  You are one of the smartest traders out there.  Unfortunately you like to be mean to less intelligent people 😝.  Anyways, how far do you think this could run?  Thanks
👍️0
FooBarAndGrill FooBarAndGrill 2 days ago
Now, reality bites.
Cash and time to ramp up.
Will vascular surgeons switch from the old and familiar?
TBD.
👍️0
TrendTrade2016 TrendTrade2016 2 days ago
HUMA READY TO RUN AGAIN
👍️0
Tiger Money Tiger Money 2 days ago
Finally!
👍️ 1
FooBarAndGrill FooBarAndGrill 2 days ago
Approved
https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue
👍️ 1
FooBarAndGrill FooBarAndGrill 2 weeks ago
Today is Dec 9th. Dec 9th marks 10 months since HUMA's PDUFA application.
FDA has performance goals. For regular PDUFA applications the goal is 90% within 10 months.
FDA performance goals: https://www.fda.gov/media/151712/download
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
I don't know of any. But you can roll your own using eg. Amazon Transcribe.
👍️0
tm100 tm100 2 weeks ago
Is there a transcript available anywhere? Have not had any success finding a transcript
👍️0
Tiger Money Tiger Money 2 weeks ago
Good news that they don't pull the plug.  This will be accepted by RFK less than a month in office 
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
The FDA is the wall. She can't say anything.
Adding that FDA has performance goals which, in this case, are not being met.
👍️0
Tiger Money Tiger Money 2 weeks ago
You say ok.  So everything is moving forward with the fda still?  Thanks 
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
Webcast OK. Direct questions and direct answers.
👍️0
FooBarAndGrill FooBarAndGrill 2 weeks ago
Supplemental BLA. Discussed during webcast.
Replay is up. https://investors.humacyte.com/news-events/events-and-presentations
👍️0
Tiger Money Tiger Money 3 weeks ago
If they are selling for any other reason than to keep it below 5%, there will be a ton of lawsuits....
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
Stonewalled.
The family sold with the excuse to reduce below 5% holding. That's no excuse at all. They're still insiders and know exactly what's up.
👍️0
Tiger Money Tiger Money 3 weeks ago
Crazy
👍️0
FooBarAndGrill FooBarAndGrill 3 weeks ago
$HUMA It's all in the family:
Mr. Dougan is married to Dr. Niklason and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr. Dougan may be deemed to share beneficial ownership of the securities held of record by Dr. Niklason, The Niklason Living Trust and Ayabudge LLC.
👍️0
Tiger Money Tiger Money 1 month ago
Great color!  Time for the fda to let this run
👍️0
roadkilll roadkilll 2 months ago
Department of Defense's priority designation is a strong tell about the future of civilian use.
"Humacyte is currently evaluating the HAV in a phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb when saphenous veins or synthetic grafts are not feasible. The HAV has received priority designation for the treatment of vascular trauma by the United States Secretary of Defense."
Sept 22, 2023 article
.
after approval expect a quick order from DOD
👍️0
roadkilll roadkilll 2 months ago
A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
.
FDA has awarded Humacyte for two indications.
👍️0
Monksdream Monksdream 2 months ago
HUMA under $6
👍️0
FooBarAndGrill FooBarAndGrill 2 months ago
Has ANYTHING changed?
August 9, 2024 “We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.”
👍️0
Tiger Money Tiger Money 3 months ago
This company has a lot going for it, that is for sure
👍️0
FooBarAndGrill FooBarAndGrill 3 months ago
Humacyte up today on genuinely positive SA piece.
https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential
👍️0
Tiger Money Tiger Money 3 months ago
Very nice!
👍️0
Sirpeter Sirpeter 3 months ago
Wynn for the win...my horse is coming in
👍️0
Tiger Money Tiger Money 3 months ago
Great to hear from you. I bought a bunch of calls for 5 cents here for he t week expiry. I can only hope Christmas comes early…
👍️0
Sirpeter Sirpeter 3 months ago
How are ya bud...been busy...Sept sucks for stocks...only holding some WYNN calls until interest rate cuts on the 18th...have to remember to ck in once in here a while lol...hope all is good with you...talk again soon
👍️0
Tiger Money Tiger Money 3 months ago
You still around? I have a feeling go time could be soon but fda always has em all by the balls ….
👍️0
Tiger Money Tiger Money 3 months ago
Likey or dislikey? Just waiting on fda. Tech is there, proven and safe. A lot of limbs/lives saved in Ukraine because of humacyte
👍️0
Monksdream Monksdream 3 months ago
HUMA under $7

👍️0
Tiger Money Tiger Money 4 months ago
Their product is amazing. Will help so many people
👍️0
Tiger Money Tiger Money 4 months ago
Great stuff and that is what I see too. Thanks!
👍️0
Sirpeter Sirpeter 4 months ago
I sold my options here and bought shares...they're cheap
👍️0
Stern is Bald Stern is Bald 4 months ago
Very promising stock and the is an opportunity to buy the dip big time..
👍️0
Tiger Money Tiger Money 4 months ago
Ok, now that is cleared up. In all seriousness, looking for your thoughts on huma . Thanks and appreciate and hope we can work together to make some $
👍️0
Stern is Bald Stern is Bald 4 months ago
Just nonsensical jibberish about deep state blah blah blah… either wat i am 90% of tuning out the knuckleheads on this site… glad you put it out there like that easier to know not to take anything from you very seriously…
👍️0
Tiger Money Tiger Money 4 months ago
Not sure I have been called Jesus before especially since I’m not Spanish.
👍️0
Tiger Money Tiger Money 4 months ago
What? You didn’t like the coup?
👍️0
Stern is Bald Stern is Bald 4 months ago
Man are you dumb jesus…
👍️0
Sirpeter Sirpeter 4 months ago
Think the dumbacrats are here to stay...will see
👍️0
Tiger Money Tiger Money 4 months ago
Worse, they are owned by the deep state. The same deep state/military industrial complex that has completely taken over the Democratic Party.
👍️0
Sirpeter Sirpeter 4 months ago
Too politcal?
👍️0

Your Recent History

NASDAQ
HUMA
Humacyte
BIT
S21016
Societe Generale
NASDAQ
CAJWX
Canoe Global Equity Fund...
BIT
F16972
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads